Literature DB >> 23456550

Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.

Brittany G Craiglow1, Richard J Antaya.   

Abstract

Infantile hemangiomas (IH), benign vascular neoplasms, are the most common tumors of infancy and childhood. Most IH are medically insignificant; however, a proportion will require treatment because of interference with vital structures, threat of significant disfigurement, ulceration, or bleeding. This article reviews current and potential pharmacotherapeutic approaches to the treatment of IH. While corticosteroids have long been considered the mainstay of medical therapy for IH, several new treatments have recently emerged, the most promising of which is oral propranolol. Topical timolol and imiquimod are additional new therapies that may also prove to be effective, particularly for the treatment of superficial IH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456550     DOI: 10.1007/s40272-013-0008-6

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  58 in total

1.  Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.

Authors:  Lawrence H C Kim; Marcia Hogeling; Orli Wargon; Ashish Jiwane; Susan Adams
Journal:  J Pediatr Surg       Date:  2011-04       Impact factor: 2.545

2.  Complications of systemic corticosteroid therapy for problematic hemangioma.

Authors:  L M Boon; D M MacDonald; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-11       Impact factor: 4.730

3.  Effective therapy of a vascular tumor of infancy with vincristine.

Authors:  J Moore; M Lee; M Garzon; S Soffer; E Kim; R Saouaf; G del Toro; D Yamashiro; J Kandel
Journal:  J Pediatr Surg       Date:  2001-08       Impact factor: 2.545

4.  Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study.

Authors:  Nhung T C Ho; Perla Lansang; Elena Pope
Journal:  J Am Acad Dermatol       Date:  2007-01       Impact factor: 11.527

Review 5.  Current management of infantile hemangiomas.

Authors:  Sheilagh M Maguiness; Ilona J Frieden
Journal:  Semin Cutan Med Surg       Date:  2010-06

6.  Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation.

Authors:  M L Bennett; A B Fleischer; S L Chamlin; I J Frieden
Journal:  Arch Dermatol       Date:  2001-09

Review 7.  Treatment of hemangiomas of infancy.

Authors:  Victoria R Barrio; Beth A Drolet
Journal:  Dermatol Ther       Date:  2005 Mar-Apr       Impact factor: 2.851

8.  Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy.

Authors:  C F Barlow; C J Priebe; J B Mulliken; P D Barnes; D Mac Donald; J Folkman; R A Ezekowitz
Journal:  J Pediatr       Date:  1998-03       Impact factor: 4.406

Review 9.  Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas.

Authors:  L Tamayo; D M Ortiz; L Orozco-Covarrubias; C Durán-McKinster; M A Mora; E Avila; F Teixeira; R Ruiz-Maldonado
Journal:  Arch Dermatol       Date:  1997-12

10.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

View more
  6 in total

1.  Propranolol therapy for infantile hemangioma is less toxic but longer in duration than corticosteroid therapy.

Authors:  Kathryn Sawa; Arjang Yazdani; Michael J Rieder; Guido Filler
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

2.  How to Manage Disfiguring Scars in Involuted Infantile Hemangioma.

Authors:  Shunsuke Yuzuriha; Fumio Nagai; Masahiko Noguchi
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-06-06       Impact factor: 4.730

3.  Effective treatment for infantile hemangioma with long-pulsed dye laser with oral propranolol medication: a preliminary report.

Authors:  Shigeyuki Furuta; Hideaki Sato; Shiho Tsuji; Fumiko Murakami; Hiroaki Kitagawa
Journal:  Pediatr Surg Int       Date:  2016-07-26       Impact factor: 1.827

Review 4.  Propranolol treatment of subglottic hemangiomas: a review of the literature.

Authors:  Lei Wu; Xiling Wu; Xuefeng Xu; Zhimin Chen
Journal:  Int J Clin Exp Med       Date:  2015-11-15

5.  Japanese clinical practice guidelines for vascular anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  Jpn J Radiol       Date:  2020-04       Impact factor: 2.374

6.  Japanese Clinical Practice Guidelines for Vascular Anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  J Dermatol       Date:  2020-03-22       Impact factor: 4.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.